Baseline characteristics of the groups were generally well balanced, except for the mean level of antibodies to dsDNA, which were lower in group 3 (75.2 IU/ml) than either groups 1 (132.9) or 2 (120.0).
Atypical LAT and oral AP groups appeared well balanced with respect to mean age (42.1 vs 42.4 years, p = .5622), gender (43.6% vs 44.6% female, p = .5345), race, region, payer type, hospital characteristics, admitting diagnosis, admitting physician specialty, and degree of illness severity (p > .05 for all).
The two patient cohorts were well balanced in terms of age (mean 63.3 versus 63.0 years) and gender (both 56% female) distributions.
Baseline demographics and disease characteristics were generally well balanced between treatment groups, and mean baseline oral corticosteroid and MTX doses were comparable (see online supplementary table S1).
A comparison of the baseline characteristics for patients in the biomarker substudy indicated that the treatment groups were generally well balanced with the exception of mean serum CRP level-, wasch was numerically, but not statistically (data not shown), lower in the placebo group (1.2 µg/ml) compared with the golimumab 50-mg (1.9 µg/ml) and 100-mg (1.8 µg/ml) groups of the substudy.
The mean scores were well balanced at baseline and generally improved over time, with no statistically significant differences between the two products (P = 0.577).
Demographic and baseline characteristics were well balanced (51.1% female, 80.3% Caucasian, mean age ∼53 years, BMI ∼31 kg/m, diabetes duration ∼3 years, baseline mean A1C8.8%%, and FPG 10.6 mmol/l).
The mean age was, however, well balanced, the proportions of those younger than 65 years being about 60%.
The mean duration of diabetes was well balanced between the real-world patients and the CARDS participants.
Baseline characteristics were well balanced in both treatment arms, with a baseline mean CD4 count of 390 cells/mm and HIV-1 RNA of 4.8 log10 copies/mL.
